Haematologica (Jan 2008)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

  • Henk M. Lokhorst,
  • Ingo Schmidt-Wolf,
  • Pieter Sonneveld,
  • Bronno van der Holt,
  • Hans Martin,
  • Rene Barge,
  • Uta Bertsch,
  • Jana Schlenzka,
  • Gerard M.J. Bos,
  • Sandra Croockewit,
  • Sonja Zweegman,
  • Iris Breitkreutz,
  • Peter Joosten,
  • Christof Scheid,
  • Marinus van Marwijk-Kooy,
  • Hans-Juergen Salwender,
  • Marinus H.J. van Oers,
  • Ron Schaafsma,
  • Ralph Naumann,
  • Harm Sinnige,
  • Igor Blau,
  • Michel Delforge,
  • Okke de Weerdt,
  • Pierre Wijermans,
  • Shulamiet Wittebol,
  • Ulrich Duersen,
  • Edo Vellenga,
  • Hartmut Goldschmidt

DOI
https://doi.org/10.3324/haematol.11644
Journal volume & issue
Vol. 93, no. 1

Abstract

Read online

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p